MCID: PLY018
MIFTS: 56

Polycythemia

Categories: Blood diseases, Immune diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Polycythemia

Summaries for Polycythemia

MalaCards based summary : Polycythemia, also known as polycythemia vera, is related to erythropoietin polycythemia and budd-chiari syndrome. An important gene associated with Polycythemia is CD177 (CD177 Molecule), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetazolamide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 Polycythemia (also known as polycythaemia or polyglobulia) is a disease state in which the hematocrit... more...

Related Diseases for Polycythemia

Diseases in the Polycythemia family:

Primary Polycythemia Acquired Polycythemia
Polycythemia Due to Hypoxia Autosomal Dominant Secondary Polycythemia

Diseases related to Polycythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
id Related Disease Score Top Affiliating Genes
1 erythropoietin polycythemia 33.6 EPO EPOR JAK2
2 budd-chiari syndrome 31.5 CALR F5 JAK2 MPL
3 poems syndrome 28.6 EPO TET2 TFRC THPO
4 polycythemia vera, somatic 12.3
5 primary polycythemia 12.0
6 acquired polycythemia 12.0
7 stress polycythemia 12.0
8 dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease 11.9
9 physiological polycythemia 11.7
10 autosomal recessive secondary polycythemia not associated with vhl gene 11.7
11 multiple paragangliomas associated with polycythemia 11.7
12 dehydration polycythemia 11.7
13 polycythemia due to hypoxia 11.7
14 autosomal dominant secondary polycythemia 11.7
15 hypermanganesemia with dystonia 1 11.7
16 erythrocytosis, somatic 11.6
17 erythrocytosis, familial, 2 11.2
18 myeloproliferative neoplasm 11.1
19 hemangioblastoma 11.1
20 erythromelalgia 11.1
21 aquagenic pruritus 11.1
22 chronic mountain sickness 11.1
23 fumarase deficiency 10.9
24 leiomyoma 10.7
25 leiomyomatosis 10.7
26 pulmonary arterio-veinous fistula 10.7
27 plethora of newborn 10.7
28 pseudopolycythaemia 10.7
29 isolated delta-storage pool disease 10.6 EGLN1 EPAS1
30 essential thrombocythemia 10.6
31 split hand/foot malformation x-linked 10.5 EPO JAK2 MPL
32 inflammatory leiomyosarcoma 10.5 EPO EPOR VHL
33 pontocerebellar hypoplasia type 2b 10.4 EPO IL3 JAK2
34 charcot-marie-tooth disease, type 4c 10.4 EPO TET2
35 hypocalciuric hypercalcemia, type iii 10.4 EPO KITLG
36 gata1-related x-linked cytopenia 10.3 HIF1A VHL
37 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.3 EGLN1 HIF1A VHL
38 exertional headache 10.3 EPO EPOR KITLG
39 temporal lobe epilepsy 10.3 JAK2 KITLG TET2
40 inflammatory bowel disease 18 10.3 MPL THPO
41 central nervous system vasculitis 10.3 EPAS1 HIF1A VHL
42 pre-malignant neoplasm 10.3 HBB TET2
43 hypotrichosis, congenital, with juvenile macular dystrophy 10.3 MPL THPO
44 cleft lip palate dysmorphism kumar type 10.2 EPAS1 HIF1A VHL
45 thrombosis 10.2
46 leukemia 10.2
47 acute leukemia 10.1 EPO EPOR HBB JAK2
48 blood coagulation disease 10.1 EPO MPL THPO
49 nephronophthisis 15 10.1 JAK2 STAT5A TET2
50 thrombocytopenia, congenital amegakaryocytic 10.0 IL3 MPL THPO

Graphical network of the top 20 diseases related to Polycythemia:



Diseases related to Polycythemia

Symptoms & Phenotypes for Polycythemia

MGI Mouse Phenotypes related to Polycythemia:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 CALR EGLN1 EPO EPOR HIF1A JAK2
2 growth/size/body region MP:0005378 10.25 STAT5A TET2 TFRC VHL CALR EGLN1
3 hematopoietic system MP:0005397 10.25 CD177 EGLN1 EPAS1 EPO EPOR HIF1A
4 cardiovascular system MP:0005385 10.24 CALR EGLN1 EPAS1 EPO EPOR F5
5 embryo MP:0005380 10.23 EPO EPOR F5 HIF1A JAK2 KITLG
6 homeostasis/metabolism MP:0005376 10.21 EPOR F5 HIF1A JAK2 KITLG MPL
7 immune system MP:0005387 10.17 HIF1A JAK2 KITLG MPL STAT5A TET2
8 liver/biliary system MP:0005370 9.93 EGLN1 EPAS1 EPO EPOR F5 HIF1A
9 integument MP:0010771 9.91 EGLN1 EPO F5 HIF1A JAK2 KITLG
10 mortality/aging MP:0010768 9.8 F5 HIF1A JAK2 KITLG MPL STAT5A
11 normal MP:0002873 9.23 JAK2 STAT5A TET2 TFRC VHL EPO

Drugs & Therapeutics for Polycythemia

Drugs for Polycythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 293)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4,Phase 1,Phase 2 59-66-5 1986
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3 Racepinephrine Approved Phase 4
4
Zinc Approved Phase 4 7440-66-6 32051 23994
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Anticonvulsants Phase 4,Phase 1,Phase 2
7 Carbonic Anhydrase Inhibitors Phase 4,Phase 1,Phase 2
8 diuretics Phase 4,Phase 1,Phase 2
9 Natriuretic Agents Phase 4,Phase 1,Phase 2
10 Epinephryl borate Phase 4
11 Hypoglycemic Agents Phase 4,Phase 2,Phase 3
12 insulin Phase 4
13 Insulin, Globin Zinc Phase 4
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
15
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
16
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
17
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
18
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
19
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
20
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
23
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
24
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
25
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
26
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
27
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
28
Morphine Approved, Investigational Phase 3 57-27-2 5288826
29
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
30
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
31
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
32
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
33
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
34 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
35
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
36
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
37 Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
38
Benzocaine Approved Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
39
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
40
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
41
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
42
Testosterone Approved, Investigational Phase 3 58-22-0 6013
43
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
44 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
45 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
46 Analgesics Phase 3,Phase 2,Phase 1
47 Anesthetics Phase 3
48 Anesthetics, Dissociative Phase 3
49 Anesthetics, General Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 279)

id Name Status NCT ID Phase Drugs
1 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes Withdrawn NCT00160485 Phase 4 Glyburide;Insulin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
8 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
9 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
10 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
11 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
12 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
13 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
14 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
15 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
20 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
21 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
22 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
23 Metformin in Obese Non-diabetic Pregnant Women Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
24 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Recruiting NCT02292446 Phase 3 Ruxolitinib
25 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Recruiting NCT02577926 Phase 3 Ruxolitinib;BAT
26 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Active, not recruiting NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
27 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Active, not recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
28 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
29 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3 ruxolitinib tablets
30 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
31 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
32 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
33 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
36 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
37 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
38 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
39 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
40 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
41 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
42 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
43 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
44 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
45 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
46 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
47 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
48 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
49 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
50 Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis Completed NCT01423058 Phase 1, Phase 2 Momelotinib

Search NIH Clinical Center for Polycythemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: polycythemia

Genetic Tests for Polycythemia

Genetic tests related to Polycythemia:

id Genetic test Affiliating Genes
1 Polycythemia 29
2 Polycythaemia 29

Anatomical Context for Polycythemia

MalaCards organs/tissues related to Polycythemia:

39
Bone, Bone Marrow, Myeloid, Liver, T Cells, Testes, Kidney

Publications for Polycythemia

Articles related to Polycythemia:

(show top 50) (show all 1102)
id Title Authors Year
1
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. ( 27884974 )
2017
2
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. ( 28934680 )
2017
3
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis. ( 28794380 )
2017
4
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. ( 28674362 )
2017
5
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. ( 28819279 )
2017
6
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. ( 28698883 )
2017
7
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. ( 28949941 )
2017
8
Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia. ( 28000848 )
2017
9
Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ( 27784744 )
2017
10
From anemia to polycythemia in 4 weeks. ( 28878919 )
2017
11
Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. ( 28824072 )
2017
12
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. ( 28622623 )
2017
13
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( 27991718 )
2017
14
Associations of high altitude polycythemia with polymorphisms in EPHA2 and AGT in Chinese Han and Tibetan populations. ( 28881807 )
2017
15
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. ( 28699191 )
2017
16
Recurrent Twin-Twin Transfusion Syndrome (rTTTS) and Twin Anemia Polycythemia Sequence (TAPS) after fetoscopic laser surgery (FLS): size (of the cannula) does matter. ( 28925589 )
2017
17
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. ( 28456851 )
2017
18
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. ( 28685840 )
2017
19
Can pegylated interferon improve the outcome of polycythemia vera patients? ( 28086927 )
2017
20
Can color difference on the maternal side of the placenta distinguish between acute peripartum twin-twin transfusion syndrome and twin anemia-polycythemia sequence? ( 28864011 )
2017
21
Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. ( 28935989 )
2017
22
Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. ( 28781268 )
2017
23
MLF1IP promotes normal erythroid proliferation and is involved in the pathogenesis of polycythemia vera. ( 28173615 )
2017
24
Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera. ( 28877745 )
2017
25
In the era of next generation sequencing, is the cytogenetic analysis still important in polycythemia vera? ( 28702402 )
2017
26
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. ( 28601551 )
2017
27
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. ( 28068330 )
2017
28
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. ( 28680586 )
2017
29
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. ( 28228104 )
2017
30
Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a case report. ( 28320457 )
2017
31
Progression of primary myelofibrosis to polycythemia vera: A case report. ( 28700486 )
2017
32
Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. ( 27684959 )
2017
33
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. ( 28860447 )
2017
34
Sequential Analysis of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals an Association between Mutational Status and Clinical Outcome. ( 27997717 )
2016
35
Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population. ( 27858230 )
2016
36
Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). ( 26917989 )
2016
37
No Benefit of BCR-ABL1 Screening in Polycythemia. ( 27630861 )
2016
38
Minihepcidin peptides as disease modifiers in mice affected by I^-thalassemia and polycythemia vera. ( 27154187 )
2016
39
Twin anemia polycythemia sequence: a single center experience and literature review. ( 27597647 )
2016
40
Coexistence of gain-of-function JAK2 germline mutations with JAK2V617F in polycythemia vera. ( 27647865 )
2016
41
A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation. ( 27956534 )
2016
42
PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. ( 27161708 )
2016
43
Erythroblastosis of the Donor Twin of Twin Anemia-Polycythemia Sequence. ( 27549671 )
2016
44
Hydroxyurea for Treatment of Nephrotic Syndrome AssociatedA With Polycythemia Vera. ( 27133437 )
2016
45
Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial. ( 27102499 )
2016
46
Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report. ( 27196481 )
2016
47
Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis. ( 27151728 )
2016
48
Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ( 26614694 )
2016
49
Erythrocytosis due to presumed polycythemia vera. ( 27618352 )
2016
50
Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. ( 27431664 )
2016

Variations for Polycythemia

Copy number variations for Polycythemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 251119 9 25500000 28100000 Mutation JAK2 polycythaemia
2 251120 9 25500000 28100000 Mutation V617F polycythaemia
3 253987 9 4985245 5128183 Mutation JAK2 polycythaemia

Expression for Polycythemia

Search GEO for disease gene expression data for Polycythemia.

Pathways for Polycythemia

Pathways related to Polycythemia according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 EPO EPOR IL3 JAK2 KITLG MPL
2
Show member pathways
13.43 EPO EPOR IL3 JAK2 KITLG MPL
3
Show member pathways
13.21 CD177 F5 HBB IL3 JAK2 MPL
4 12.57 EGLN1 EPAS1 HIF1A KITLG STAT5A VHL
5 12.44 IL3 JAK2 KITLG MPL STAT5A
6
Show member pathways
11.84 EPO EPOR IL3 JAK2 KITLG STAT5A
7 11.83 EPO IL3 KITLG MPL THPO
8
Show member pathways
11.8 EPO EPOR JAK2 STAT5A
9 11.78 EPO EPOR IL3 JAK2 STAT5A
10
Show member pathways
11.74 EPAS1 HIF1A VHL
11 11.65 EGLN1 EPO HIF1A TFRC VHL
12 11.61 EPOR IL3 KITLG THPO
13 11.59 EGLN1 EPO HIF1A TFRC
14 11.57 HIF1A JAK2 STAT5A
15 11.49 EGLN1 EPO HIF1A VHL
16 11.42 EPO IL3 KITLG
17 11.42 EPO EPOR IL3 KITLG TFRC THPO
18
Show member pathways
11.41 EPO EPOR IL3 JAK2 MPL STAT5A
19 11.39 EPO IL3 KITLG STAT5A
20
Show member pathways
11.38 EPO EPOR JAK2
21 11.28 EGLN1 EPO HIF1A
22 11.19 JAK2 MPL STAT5A THPO
23 11.15 EGLN1 EPAS1 EPO VHL
24 10.91 JAK2 STAT5A
25 10.85 EPAS1 VHL
26 10.78 HIF1A VHL

GO Terms for Polycythemia

Cellular components related to Polycythemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CALR EPO EPOR F5 HBB IL3
2 extracellular space GO:0005615 9.23 CALR EPO F5 HBB IL3 KITLG
3 endocytic vesicle lumen GO:0071682 9.16 CALR HBB

Biological processes related to Polycythemia according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 CALR EPO IL3 JAK2 KITLG
2 blood coagulation GO:0007596 9.83 CD177 F5 HBB JAK2
3 response to hypoxia GO:0001666 9.78 EGLN1 EPAS1 EPO HIF1A
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 IL3 JAK2 KITLG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 EPO IL3 JAK2
6 cellular iron ion homeostasis GO:0006879 9.71 EGLN1 HIF1A TFRC
7 cytokine-mediated signaling pathway GO:0019221 9.71 EPOR IL3 JAK2 MPL
8 positive regulation of Ras protein signal transduction GO:0046579 9.58 EPO KITLG
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 JAK2 STAT5A
10 erythrocyte differentiation GO:0030218 9.54 EPAS1 EPO JAK2
11 oxygen homeostasis GO:0032364 9.51 EGLN1 HIF1A
12 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.49 EPAS1 HIF1A
13 hemoglobin biosynthetic process GO:0042541 9.46 EPO HIF1A
14 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.43 KITLG THPO
15 embryonic hemopoiesis GO:0035162 9.33 HIF1A IL3 KITLG
16 erythropoietin-mediated signaling pathway GO:0038162 9.32 EPO EPOR
17 thrombopoietin-mediated signaling pathway GO:0038163 9.26 MPL THPO
18 positive regulation of DNA replication GO:0045740 9.26 CALR EPO IL3 KITLG
19 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 EGLN1 EPAS1 EPO HIF1A VHL

Molecular functions related to Polycythemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 CALR CD177 EGLN1 EPAS1 EPO EPOR
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 IL3 JAK2 KITLG

Sources for Polycythemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....